TY - JOUR T1 - Targeting Fibroblast Growth Factor Receptor (FGFR) and Phosphoinositide 3-kinase (PI3K) Signaling Pathways in Medulloblastoma Cell Lines JF - Anticancer Research JO - Anticancer Res SP - 53 LP - 66 DO - 10.21873/anticanres.13925 VL - 40 IS - 1 AU - STEFAN HOLZHAUSER AU - MONIKA LUKOSEVICIUTE AU - TEODORA ANDONOVA AU - RAMONA G. URSU AU - TINA DALIANIS AU - MALIN WICKSTRĂ–M AU - OURANIA N. KOSTOPOULOU Y1 - 2020/01/01 UR - http://ar.iiarjournals.org/content/40/1/53.abstract N2 - Background/Aim: Medulloblastoma (MB) accounts for ~20% of pediatric malignant central nervous system tumors. Treatment strategies, including surgery, radiation therapy and/or chemotherapy, are effective, but recurrence and metastasis frequently occur. Therefore, novel therapies are required. Herein, the effects of fibroblast growth factor receptor (FGFR) and phosphoinositide 3-kinase (PI3K) inhibitors on MB cells lines were evaluated. Materials and Methods: MB cell lines (UW228-3, DAOY, Med8a, D425, D283) were tested for sensitivity to FGFR (AZD4547) and PI3K (BEZ235 and BYL719) inhibitors by viability, cytotoxicity, apoptosis, and proliferation assays. Results: Single treatments with FGFR and PI3K inhibitors decreased viability and proliferation in a dose-dependent pattern in most cell lines. Combinination of the two type of drugs, increased sensitivity, especially of the most resistant cell line UW228-3. Conclusion: Combination treatments with FGFR and PI3K inhibitors were superior to single treatments with FGFR and PI3K inhibitors, especially with BEZ235, for MB cell lines. ER -